Abliva (formerly NeuroVive Pharmaceutical) is a company engaged in the research and development of mitochondrial medicine. Its product portfolio includes NeuroSTAT, a drug candidate for the treatment of traumatic brain injuries; and ToxPhos for the mitochondrial toxicity test. The Company is also developing drugs for mitochondrial genetic disorders, mitochondrial myopathies and hepatocellular carcinoma. It has collaboration agreements with several pharmaceutical companies, and a preclinical collaboration agreement with a hospital for research in mitochondrial medicine field.
Market capitalization (7-Jun-2021)
Closing stock price (7-Jun-2021)
When was Abliva founded?
Abliva was founded in 1998.
Who are Abliva key executives?
Abliva's key executives are David Laskow-Pooley, David Bejker and Jan Törnell.
How many employees does Abliva have?
Abliva has 9 employees.
Who are Abliva competitors?
Competitors of Abliva include ViewPoint Therapeutics, Acousia Therapeutics and Nordic Nanovector.
Where is Abliva headquarters?
Abliva headquarters is located at Medicon Village, Lund.
Where are Abliva offices?
Abliva has an office in Lund.
How many offices does Abliva have?
Abliva has 1 office.
Receive alerts for 300+ data fields across thousands of companies